青蒿琥酯通过调节Th17/Treg平衡减轻慢性移植物抗宿主病
该研究以B10D2→BALB/c小鼠建立cGVHD模型,在第28天起每日腹腔注射青蒿琥酯1 mg/kg,发现其减轻临床与病理损伤并延长生存,同时降低外周血、脾脏及体外CD4+T细胞中Th17比例、升高Treg比例、降低Th17/Treg比值。
要点
- 青蒿琥酯组小鼠cGVHD临床症状与皮肤、肺脏病理损伤较对照组减轻。
- 青蒿琥酯组生存时间较对照组延长[(55.71±6.99)d对(46.57±7.83)d,P=0.020]。
- 青蒿琥酯降低外周血、脾脏及体外Th17比例、升高Treg比例及降低Th17/Treg比值。
核心结论
- 青蒿琥酯可通过减少Th17细胞及增加Treg细胞、恢复Th17/Treg平衡,减轻cGVHD的临床与病理学损伤,从而发挥抗cGVHD作用,为cGVHD新药(如青蒿素类)研发提供新思路。
研究设计与样本
- 将B10D2小鼠骨髓细胞和脾脏细胞混合悬液经尾静脉输入近交系雌性BALB/c小鼠建立cGVHD模型,分青蒿琥酯实验组与丙酮对照组腹腔注射治疗。
- BMT后第28天起每日腹腔注射丙酮溶解的青蒿琥酯1 mg/kg,观察临床评分、生存和组织病理学改变,流式细胞术分析外周血和脾脏Th17与Treg比例。
- 免疫磁珠分选BALB/c小鼠脾脏CD4+T细胞,分别予丙酮和青蒿琥酯干预72 h,流式细胞术分析两组Th17/Treg细胞比例。
主要发现
- 实验组小鼠cGVHD临床症状较对照组明显减轻,生存时间延长[(55.71±6.99)d对(46.57±7.83)d,χ²=5.457,P=0.020]。
- 实验组小鼠皮肤及肺脏cGVHD病理损伤较对照组轻。
- 实验组外周血、脾脏Th17细胞比例均低于对照组[(0.58±0.19)%对(1.51±0.18)%,t=7.233,P<0.001;(0.71±0.18)%对(1.48±0.38)%,t=3.653,P=0.011]。
- 实验组外周血、脾脏Treg细胞比例均高于对照组[(8.40±0.23)%对(4.45±0.04)%,t=15.680,P<0.001;(10.48±0.48)%对(6.62±0.24)%,t=6.590,P=0.003]。
- 实验组外周血、脾脏Th17/Treg细胞比值均低于对照组(0.09±0.03对0.34±0.05,t=7.621,P=0.002;0.06±0.02对0.19±0.03,t=6.993,P=0.002)。
关键数值与推荐
- 体外培养小鼠脾脏CD4+T细胞,青蒿琥酯干预组较对照组Th17细胞比例减低[(0.82±0.37)%对(3.39±1.22)%,t=4.044,P=0.007]。
- 体外培养小鼠脾脏CD4+T细胞,青蒿琥酯干预组较对照组Treg细胞比例增高[(34.63±1.29)%对(14.28±1.69)%,t=19.119,P<0.001]。
- 体外培养小鼠脾脏CD4+T细胞,青蒿琥酯干预组较对照组Th17/Treg细胞比值下降(0.24±0.09对0.02±0.01,t=4.780,P=0.003)。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the effects of artesunate treatment on chronic graft-versus-host disease (cGVHD). Methods: Recipient BALB/c mice received 8 × 10(6) bone marrow cells with 8×10(6) spleen cells from B10D2 mice. Artesunate solubilized in acetone was injected intraperitoneally every day at the dose of 1 mg/kg at Day 28 after BMT. The clinical scores, survival and histopathological damage were analyzed. The frequency of Th17 and Tregs in PB and spleens from the mice were evaluated by flow cytometry. In addition, CD4(+) T cells from the spleens of mice were cultured in vitro, then stimulated with artesunate, the frequency of Th17 and Tregs in these splenocytes were evaluated by flow cytometry. Results: Artesunate administration diminished clinical and histopathological damage, and improved the survival of cGVHD mice[(46.57±7.83)% vs (55.71±6.99)%, χ(2)=5.457, P=0.020]; Artesunate contributed to Tregs development [(4.45±0.04)% vs (8.40±0.23)%, t=15.679, P<0.001; (6.62±0.24)% vs (10.48±0.48)%, t=6.587, P=0.003] while decreased Th17 cells [(1.51±0.18)% vs (0.58±0.19)%, t=7.233, P<0.001; (1.48±0.38)% vs (0.71±0.18)%, t=3.653, P=0.011] expressions in both PB and spleens, and decreased the Th17/Treg ratio (0.34±0.05 vs 0.09±0.03, t=7.621, P=0.002; 0.19±0.03 vs 0.06±0.02, t=6.993, P=0.002). Moreover, artesunate suppressed the Th17 cells expressions [(0.82±0.37) % vs (3.39±1.22) %, t=4.044, P=0.007] and contributed to Tregs development [(34.63±1.29) % vs (14.28±1.69) %, t=19.119, P<0.001], and also decreased the Th17/Treg ratio (0.24±0.09 vs 0.02±0.01, t=4.780, P=0.003) in vitro. Conclusions: Artesunate suppressed the Th17 cells expressions and contributed to Tregs development, which provided new sights into the development of a novel drug for cGVHD, e.g., artemisinin. 目的: 探讨青蒿琥酯抗慢性移植物抗宿主病(cGVHD)的作用及可能机制。 方法: 将B10D2小鼠的骨髓细胞和脾脏细胞混合悬液通过尾静脉输入近交系雌性BALB/c小鼠体内建立cGVHD模型,分别予青蒿琥酯(实验组)和丙酮腹腔(对照组)注射治疗。观察两组小鼠的cGVHD临床表现、生存时间和组织病理学改变;应用流式细胞术分析小鼠外周血和脾脏Th17和Treg细胞比例;免疫磁珠分选BALB/c小鼠脾脏CD4(+)T细胞,分别予丙酮和青蒿琥酯进行干预72 h,流式细胞术分析两组Th17/Treg细胞比例。 结果: ①实验组小鼠cGVHD临床症状较对照组明显减轻,生存时间延长[(55.71±6.99)d对(46.57±7.83)d,χ(2)=5.457,P=0.020]。②实验组小鼠皮肤及肺脏cGVHD病理损伤较轻。③与对照组比较,实验组小鼠外周血、脾脏Th17细胞比例均降低[(0.58±0.19)%对(1.51±0.18)%,t=7.233,P<0.001;(0.71±0.18)%对(1.48±0.38)%,t=3.653,P=0.011],Treg细胞比例增高[(8.40±0.23)%对(4.45±0.04)%,t=15.680,P<0.001;(10.48±0.48)%对(6.62±0.24)%,t=6.590,P=0.003],Th17/Treg细胞比值均下降(0.09±0.03对0.34±0.05,t=7.621,P=0.002;0.06±0.02对0.19±0.03,t=6.993,P=0.002)。④体外培养小鼠脾脏CD4(+)T细胞,青蒿琥酯干预组较对照组Th17细胞比例减低[(0.82±0.37)%对(3.39±1.22)%,t=4.044,P=0.007],Treg细胞比例明显增高[(34.63±1.29)%对(14.28±1.69)%,t=19.119,P<0.001],Th17/Treg细胞比值下降(0.24±0.09对0.02±0.01,t=4.780,P=0.003)。 结论: 青蒿琥酯可通过减少Th17细胞及增加Treg细胞,恢复Th17/Treg平衡,减轻cGVHD的临床与病理学损伤,从而发挥抗cGVHD作用。.
引用
- Chen XM, Weng JY, Lai PL, et al. [Artesunate attenuate chronic graft-versus-host disease by regulating Th17/Treg balance]. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 30704231. doi:10.3760/cma.j.issn.0253-2727.2019.01.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。